What is the recommended management for polymyalgia rheumatica in patients over 50, including initial glucocorticoid therapy, tapering schedule, monitoring of inflammatory markers, calcium/vitamin D supplementation, bisphosphonate use, screening for giant cell arteritis, and steroid‑sparing agents?

Management of Polymyalgia Rheumatica

Start prednisone at 12.5-25 mg daily (not higher than 30 mg, not lower than 7.5 mg), taper to 10 mg within 4-8 weeks, then reduce by 1 mg every 4 weeks until discontinuation while monitoring disease activity and inflammatory markers every 4-8 weeks in the first year. 1

Initial Glucocorticoid Therapy

The 2015 EULAR/ACR guidelines provide the definitive framework for PMR management. Glucocorticoids are strongly recommended over NSAIDs as primary treatment 1. The initial dose should be individualized within the 12.5-25 mg prednisone equivalent range based on:

• Higher doses (20-25 mg): Patients with high relapse risk and low adverse event risk
• Lower doses (12.5-15 mg): Patients with diabetes, osteoporosis, glaucoma, or other glucocorticoid-sensitive comorbidities 1

Avoid initial doses ≤7.5 mg/day (conditionally discouraged) and never exceed 30 mg/day (strongly contraindicated) 1. Single daily dosing is preferred over divided doses, except when prominent night pain occurs during low-dose tapering (<5 mg daily) 1.

Intramuscular methylprednisolone (120 mg every 3 weeks) can be considered as an alternative to oral glucocorticoids 1.

Tapering Schedule

The tapering protocol follows a structured three-phase approach 1:

Phase 1 - Initial Tapering (Weeks 0-8):

• Reduce from starting dose to 10 mg/day prednisone within 4-8 weeks

Phase 2 - Slow Tapering (After remission achieved):

• Decrease by 1 mg every 4 weeks (or 1.25 mg using alternate-day schedules like 10/7.5 mg)
• Continue until complete discontinuation if remission maintained
• Research supports that slow tapering (<1 mg/month) reduces relapses compared to faster regimens 2

Phase 3 - Relapse Management:

• Increase to pre-relapse dose
• Gradually decrease within 4-8 weeks back to the dose where relapse occurred
• Resume slow tapering 1

Monitoring Protocol

Follow-up schedule 1:

• First year: Every 4-8 weeks
• Second year: Every 8-12 weeks
• Additional visits: During relapses or tapering adjustments

At each visit, document:

• Disease activity (pain, stiffness, functional status)
• Laboratory markers (ESR, CRP)
• Glucocorticoid-related adverse effects
• Comorbidities and concomitant medications
• Risk factors for relapse/prolonged therapy 1

Patients require rapid access to healthcare providers to report flares and adverse events 1.

Bone Protection and Gastroprotection

While the 2015 EULAR/ACR guidelines don't explicitly address calcium/vitamin D or bisphosphonates, recent evidence demonstrates their importance. Bisphosphonates reduce fragility fractures by approximately 0.92% absolute risk reduction (number needed to treat = 109) in PMR patients on glucocorticoids 3. This translates to preventing one fracture per year for every 100 patients treated.

Standard of care includes:

• Calcium and vitamin D supplementation for all patients on long-term glucocorticoids
• Bisphosphonates for patients at high fracture risk (age >65, prior fractures, prolonged glucocorticoid use)
• Gastroprotection (PPIs/H2RAs) is widely prescribed (78.6% of patients) 3, though evidence for preventing serious GI events in PMR specifically is limited

Male patients and those in more deprived areas receive bisphosphonates less frequently—a disparity requiring clinical attention 3.

Giant Cell Arteritis Screening

Critical vigilance for GCA is mandatory given the overlap between these conditions and risk of vision loss. Screen for:

• New-onset headache (especially temporal)
• Visual disturbances or vision loss
• Jaw claudication
• Scalp tenderness
• Constitutional symptoms beyond typical PMR

Refer to specialist immediately for 1:

• Atypical presentations (peripheral arthritis, systemic symptoms, low inflammatory markers, age <60)
• Suspected GCA features
• PMR refractory to glucocorticoids
• Relapses or need for prolonged therapy
• High risk or evidence of glucocorticoid-related adverse effects

Temporal artery ultrasound showing "halo sign" or temporal artery biopsy may be needed for GCA confirmation 4, 5.

Steroid-Sparing Agents

Methotrexate (7.5-10 mg/week orally) should be considered early in patients with 1:

• High risk for relapse or prolonged therapy
• Risk factors for glucocorticoid adverse events
• Relevant comorbidities (diabetes, osteoporosis, glaucoma)
• Relapse during follow-up
• Inadequate response to glucocorticoids
• Experiencing glucocorticoid-related adverse events

Methotrexate reduces cumulative glucocorticoid exposure by 20-44% and relapses by 36-54% 4, 2.

TNF-α blocking agents are strongly contraindicated for PMR treatment 1.

Tocilizumab has shown efficacy in GCA and recent PMR trials, with FDA approval of sarilumab for refractory PMR representing a major therapeutic advance 6, 7. These biologics should be considered when methotrexate is insufficient or contraindicated.

Common Pitfalls

• Starting doses >30 mg: Increases adverse effects without improving outcomes 1
• Starting doses ≤7.5 mg: Associated with higher relapse rates 1
• Rapid tapering: Increases relapse risk; maintain 1 mg/4-week reductions 1, 2
• Missing GCA: Always assess for cranial symptoms; delayed diagnosis risks permanent vision loss 4, 5
• Inadequate bone protection: Fractures occur frequently; prophylaxis is essential 3
• Failure to consider methotrexate early: Waiting until complications develop misses opportunity for glucocorticoid sparing 1

Exercise and Patient Education

Individualized exercise programs targeting muscle mass maintenance, function preservation, and fall prevention are conditionally recommended, especially for older patients on long-term glucocorticoids 1. Patient education should cover disease impact, treatment expectations, comorbidity management, and disease predictors 1.